Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tharwat Haj

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Journal of Clinical Immunology|October 6, 2010
IVIg attenuates TLR-9 activation in B cells from SLE patientsAharon Kessel, Regina Peri, Tharwat Haj, et al.
The Israel Medical Association Journal : IMAJ|June 5, 2015
Interferon-gamma-release assay prevents unnecessary tuberculosis therapyVered Schichter-Konfino, Katalin Halasz, Galia Grushko, et al.
Stem Cells and Development|April 19, 2022
The Modulatory Effect of Adipose-Derived Stem Cells on Endometrial Polyp FibroblastsReema Fadoul, Tharwat Haj Khalil, Idan Redenski, et al.
Arthritis Research & Therapy|June 16, 2012
Semaphorin 3A is a marker for disease activity and a potential immunoregulator in systemic lupus erythematosusZahava Vadasz, Tharwat Haj, Katalin Halasz, et al.
Rheumatology International|April 22, 2015
Semaphorin 3A: an immunoregulator in systemic sclerosisDoron Rimar, Yuval Nov, Itzhak Rosner, et al.
International Journal of Molecular Sciences|December 30, 2025
Pro-Inflammatory Macrophage Phenotype Skewing Induced by Tumor Treating Fields (TTFields)Tal Kan, Yiftah Barsheshet, Tharwat Haj Khalil, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 28, 2014
Brief report: lysyl oxidase is a potential biomarker of fibrosis in systemic sclerosisDoron Rimar, Itzhak Rosner, Yuval Nov, et al.
Frontiers in Medicine|February 26, 2021
COVID-19 Vaccine Acceptance Among Dental Professionals Based on Employment Status During the PandemicAsaf Zigron, Amiel A Dror, Nicole G Morozov, et al.
International Journal of Molecular Sciences|November 26, 2022
Tumor Treating Fields (TTFields) Concomitant with Immune Checkpoint Inhibitors Are Therapeutically Effective in Non-Small Cell Lung Cancer (NSCLC) In Vivo ModelYiftah Barsheshet, Tali Voloshin, Boris Brant, et al.
International Journal of Cancer|February 27, 2026
Efficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma, with and without gemcitabine/nab-paclitaxelTal Kan, Tharwat Haj Khalil, Yiftah Barsheshet, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal of Clinical Immunology|October 6, 2010
IVIg attenuates TLR-9 activation in B cells from SLE patientsAharon Kessel, Regina Peri, Tharwat Haj, et al.
The Israel Medical Association Journal : IMAJ|June 5, 2015
Interferon-gamma-release assay prevents unnecessary tuberculosis therapyVered Schichter-Konfino, Katalin Halasz, Galia Grushko, et al.
Stem Cells and Development|April 19, 2022
The Modulatory Effect of Adipose-Derived Stem Cells on Endometrial Polyp FibroblastsReema Fadoul, Tharwat Haj Khalil, Idan Redenski, et al.
Arthritis Research & Therapy|June 16, 2012
Semaphorin 3A is a marker for disease activity and a potential immunoregulator in systemic lupus erythematosusZahava Vadasz, Tharwat Haj, Katalin Halasz, et al.
Rheumatology International|April 22, 2015
Semaphorin 3A: an immunoregulator in systemic sclerosisDoron Rimar, Yuval Nov, Itzhak Rosner, et al.
International Journal of Molecular Sciences|December 30, 2025
Pro-Inflammatory Macrophage Phenotype Skewing Induced by Tumor Treating Fields (TTFields)Tal Kan, Yiftah Barsheshet, Tharwat Haj Khalil, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 28, 2014
Brief report: lysyl oxidase is a potential biomarker of fibrosis in systemic sclerosisDoron Rimar, Itzhak Rosner, Yuval Nov, et al.
Frontiers in Medicine|February 26, 2021
COVID-19 Vaccine Acceptance Among Dental Professionals Based on Employment Status During the PandemicAsaf Zigron, Amiel A Dror, Nicole G Morozov, et al.
International Journal of Molecular Sciences|November 26, 2022
Tumor Treating Fields (TTFields) Concomitant with Immune Checkpoint Inhibitors Are Therapeutically Effective in Non-Small Cell Lung Cancer (NSCLC) In Vivo ModelYiftah Barsheshet, Tali Voloshin, Boris Brant, et al.
International Journal of Cancer|February 27, 2026
Efficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma, with and without gemcitabine/nab-paclitaxelTal Kan, Tharwat Haj Khalil, Yiftah Barsheshet, et al.
Pageof 2